Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 23 citing articles:

Viral vectored vaccines: design, development, preventive and therapeutic applications in human diseases
Shen Wang, Bo Liang, Weiqi Wang, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 87
Full protection from SARS-CoV-2 brain infection and damage in susceptible transgenic mice conferred by MVA-CoV2-S vaccine candidate
Javier Villadiego, Juan García‐Arriaza, Reposo Ramírez‐Lorca, et al.
Nature Neuroscience (2023) Vol. 26, Iss. 2, pp. 226-238
Open Access | Times Cited: 29
Intranasal administration of a single dose of MVA-based vaccine candidates against COVID-19 induced local and systemic immune responses and protects mice from a lethal SARS-CoV-2 infection
Patricia Pérez, David Astorgano, Guillermo Albericio, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 27
Highly Attenuated Poxvirus-Based Vaccines Against Emerging Viral Diseases
Beatriz Perdiguero, Patricia Pérez, Laura Marcos-Villar, et al.
Journal of Molecular Biology (2023) Vol. 435, Iss. 15, pp. 168173-168173
Open Access | Times Cited: 20
Modulating the immune response to SARS-CoV-2 by different nanocarriers delivering an mRNA expressing trimeric RBD of the spike protein: COVARNA Consortium
Laura Marcos-Villar, Beatriz Perdiguero, Shubaash Anthiya, et al.
npj Vaccines (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 5
MVA-CoV2-S Vaccine Candidate Neutralizes Distinct Variants of Concern and Protects Against SARS-CoV-2 Infection in Hamsters
Robbert Boudewijns, Patricia Pérez, Adrián Lázaro-Frías, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 23
Poxvirus MVA Expressing SARS-CoV-2 S Protein Induces Robust Immunity and Protects Rhesus Macaques From SARS-CoV-2
Petra Mooij, Juan García‐Arriaza, Patricia Pérez, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 22
Vaccinia Virus Strain MVA Expressing a Prefusion-Stabilized SARS-CoV-2 Spike Glycoprotein Induces Robust Protection and Prevents Brain Infection in Mouse and Hamster Models
Marı́a M. Lorenzo, Alejandro Marín-López, Kevin Chiem, et al.
Vaccines (2023) Vol. 11, Iss. 5, pp. 1006-1006
Open Access | Times Cited: 8
Pharmacokinetic and Environmental Risk Assessment of Prime-2-CoV, a Non-Replicating Orf Virus-Based Vaccine against SARS-CoV-2
C.A. Metz, Verena Haug, Melanie Müller, et al.
Vaccines (2024) Vol. 12, Iss. 5, pp. 492-492
Open Access | Times Cited: 2
Vaccinia Virus Strain Mva Expressing a Prefusion-Stabilized SARS-CoV-2 Spike Glycoprotein Induces Robust Protection and Prevents Brain Infection in Mouse and Hamster Models
Marı́a M. Lorenzo, Alejandro Marín-López, Kevin Chiem, et al.
(2023)
Open Access | Times Cited: 5
Optimized vaccine candidate MVA-S(3P) fully protects against SARS-CoV-2 infection in hamsters
Rana Abdelnabi, Patricia Pérez, David Astorgano, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 5
Heterologous mRNA/MVA delivering trimeric-RBD as effective vaccination regimen against SARS-CoV-2: COVARNA Consortium
Laura Marcos-Villar, Beatriz Perdiguero, María López‐Bravo, et al.
Emerging Microbes & Infections (2024) Vol. 13, Iss. 1
Open Access | Times Cited: 1
Rapid Development of Modified Vaccinia Virus Ankara (MVA)-Based Vaccine Candidates Against Marburg Virus Suitable for Clinical Use in Humans
Alina Tscherne, Georgia Kalodimou, Alexandra Kupke, et al.
Vaccines (2024) Vol. 12, Iss. 12, pp. 1316-1316
Open Access | Times Cited: 1
Preclinical immune efficacy against SARS-CoV-2 beta B.1.351 variant by MVA-based vaccine candidates
Patricia Pérez, Guillermo Albericio, David Astorgano, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 4
Serum angiotensin-converting enzyme 2 as a potential biomarker for SARS-CoV-2 infection and vaccine efficacy
Matthew P. Lennol, María‐Salud García‐Ayllón, Mariano Estéban, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 6
The effect of Toll-like receptor agonists on the immunogenicity of MVA-SARS-2-S vaccine after intranasal administration in mice
Kim Thi Hoang, Stefanie Willenzon, Jasmin Ristenpart, et al.
Frontiers in Cellular and Infection Microbiology (2023) Vol. 13
Open Access | Times Cited: 3
Dendritic Cell‐Mediated Cross‐Priming by a Bispecific Neutralizing Antibody Boosts Cytotoxic T Cell Responses and Protects Mice against SARS‐CoV‐2
Rodrigo Lázaro‐Gorines, Patricia Pérez, Ignacio Heras‐Murillo, et al.
Advanced Science (2023) Vol. 10, Iss. 34
Open Access | Times Cited: 2
Lung transcriptomics of K18-hACE2 mice highlights mechanisms and genes involved in the MVA-S vaccine-mediated immune response and protection against SARS-CoV-2 infection
Alberto Gómez‐Carballa, Guillermo Albericio, Julián Montoto-Louzao, et al.
Antiviral Research (2023) Vol. 220, pp. 105760-105760
Open Access | Times Cited: 2
Trimerized S expressed by modified vaccinia virus Ankara (MVA) confers superior protection against lethal SARS-CoV-2 challenge in mice
Junda Zhu, Zhenshan Wang, Yarui Li, et al.
Journal of Virology (2024) Vol. 98, Iss. 7
Closed Access
MVA-based vaccine candidates expressing SARS-CoV-2 prefusion-stabilized spike proteins of the Wuhan, Beta or Omicron BA.1 variants protect transgenic K18-hACE2 mice against Omicron infection and elicit robust and broad specific humoral and cellular immune responses
Patricia Pérez, David Astorgano, Guillermo Albericio, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access
Rendezvous with Vaccinia Virus in the Post-smallpox Era: R&D Advances
Yuxiang Wang
Viruses (2023) Vol. 15, Iss. 8, pp. 1742-1742
Open Access | Times Cited: 1
MVA-CoV2-S vaccine candidate confers full protection from SARS-CoV-2 brain infection and damage in susceptible transgenic mice
Javier Villadiego, Juan García‐Arriaza, Reposo Ramírez‐Lorca, et al.
Research Square (Research Square) (2022)
Open Access
The MVA-CoV2-S vaccine developed at the CNB-CSIC is highly immunogenic and completely effective against SARS-CoV-2/COVID-19: future and opportunities
Juan García‐Arriaza, Mariano Esteban Rodríguez
Anales de la Real Academia Nacional de Farmacia (2022) Vol. 88, Iss. 88(05), pp. 415-426
Open Access
Page 1

Scroll to top